Over 80% of data is unstructured, which can make it harder to access and to develop insights from. With global scientific output doubling every nine years, biomedical innovation is limited by a company’s ability to make use of the large volumes of data at its disposal. Biorelate’s solutions overcome this challenge by creating a high-performance platform for curating biomedical knowledge that can be used to accelerate innovation.
Biorelate’s platform, Galactic AI, improves access to data and information. This enables drug discovery companies to gain better insights to develop new innovations. The cloud-based computing platform they have developed can organise, analyse and connect large volumes of data to save time and resources when solving complex research problems. Its high-level processing power provides real-time insights and ensures that companies keep pace with the latest research outputs and developments.
Daniel Jamieson, CEO and Founder, has set a vision for Biorelate’s growth that includes expanding product sales in existing markets and gaining traction in the US. Support from SME Leaders Programme comes at a pivotal time as he focuses on business development, product innovation and sales. He will be able to use training through the programme to further develop leadership skills, in areas such as negotiation, as the company enters a significant phase of growth.
